Search
fr-FRen-GB
Langue
× Search
"); WinPrint.document.close(); WinPrint.focus(); setTimeout(function () { WinPrint.print(); }, 500); return false; }); }); function initContactForm(contactEmailFieldValue, formTitle) { eds2_2('#dnn_ctr407_ViewEasyDNNNewsMain_ctl00_hfContactFormID').val(contactEmailFieldValue); eds2_2('#dnn_ctr407_ViewEasyDNNNewsMain_ctl00_pnlContactInputForm').css('display','block'); eds2_2('#dnn_ctr407_ViewEasyDNNNewsMain_ctl00_pnlContactFormMessageSent').css('display','none'); eds2_2('#dnn_ctr407_ViewEasyDNNNewsMain_ctl00_lblContactFormTitle').html(formTitle); } eds2_2(function ($) { if (typeof edn_fluidvids != 'undefined') edn_fluidvids.init({ selector: ['.edn_fluidVideo iframe'], players: ['www.youtube.com', 'player.vimeo.com'] }); }); /*]]>*/

MSD closes transaction to sell its Mirabel production site to FAREVA pharmaceutical group

lundi 18 janvier 2021

Joint Press release

Riom, January 18, 2021 - MSD and FAREVA, a world leader in pharmaceutical production, complete the acquisition of MSD’s Mirabel production site located in Riom (Puy-de-Dôme).

"I am delighted to have met and talked to all the employees at the Mirabel site today, I’m excited about welcoming them to FAREVA. Their high level of expertise and the quality of the site's facilities will be undeniable assets in pursuing our industrial development around the world," said Bernard FRAISSE, Chairman and CEO of FAREVA.

"We are delighted with the successful completion of this agreement, which is the result of a joint effort  between MSD and FAREVA, with the support of representatives of the Auvergne-Rhône-Alpes Region, local elected officials and State representatives," said Jean-Albert PITTALUGA, who remains at the head of the site.

The transaction includes the transfer of 352 employees to FAREVA and a substantial investment. FAREVA expects this investment will enable long-term growth and potential job creation at the site.

Media Contact MSD France
Julien AGUIAR
+33 (0)6 20 31 13 49
julien.aguiar@msd.com

Media Contact Fareva
Marie Wicart, Communication Director
communication@fareva.com

About MSD France
Established in France since 1961, MSD France is a subsidiary of Merck & Co., Inc, Kenilworth, NJ, USA, a leading biopharmaceutical company whose mission is to invent and develop drugs and vaccines targeting the world’s most challenging diseases. MSD France's goal is to provide patients and healthcare professionals with a comprehensive and innovative healthcare offer, consisting mainly of medicines, particularly in oncology and infectious diseases, and vaccines, as well as digital solutions and services. For more information, please visit www.msd-france.com or follow us on Twitter and LinkedIn.

About Fareva
Fareva, a family-owned company whose strength lies in its financial independence, is one of the world’s leading CDMOs in the pharmaceuticals, cosmetics, make-up, and industrial and homecare fields.
Fareva operates in 11 countries with 41 factories and employs more than 12 000 employees with annual revenue reaching € 1.8 billion in 2019. For further information, please come and visit us at www.fareva.com.

Name:
Email:
Subject:
Message:
x
Haut de page